Associated Papers
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population.
Ozen F et al.
Genetic Testing and Molecular Biomarkers, 2013
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Modest DP et al.
Oncology, 2012
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.
Arcila M et al.
The Journal of Molecular Diagnostics : Jmd, 2011
KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.
Licar A et al.
International Journal of Oncology, 2010
Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGap interaction.
Gremer L et al.
Biological Chemistry, 2008
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y et al.
Human Mutation, 2008
Select a paper to view details